Treatment of hyperlipidemia from Japanese evidence

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Epidemiology

Background:

• Cardiovascular disease (CVD) and coronary heart disease (CHD) prevention are key goals of hyperlipidemia treatment.
• Japan exhibits lower CHD incidence but higher stroke rates than Western countries, with differing drug dosages in clinical trials.
• Extrapolation of Western clinical trial results to Japanese patients is uncertain due to these differences.

Purpose of the Study:

• To review Japanese epidemiological and clinical studies on hyperlipidemia treatment.
• To assess the applicability of Western clinical trial findings to Japanese patients.
• To discuss the safety and efficacy of lipid-lowering therapies in Japan.

Main Methods:

• Review of Japanese epidemiological data.
• Analysis of findings from large-scale prospective randomized controlled trials (RCTs) in Japanese patients, including the MEGA and JELIS studies.
• Examination of evidence regarding hypercholesterolemia, hypertriglyceridemia, and low HDL-cholesterol associations with CHD risk.

Main Results:

• Hypercholesterolemia, hypertriglyceridemia, and low HDL-cholesterol are significantly linked to increased CHD risk in Japan.
• Lipid-lowering medication demonstrates positive effects, even in individuals at lower risk.
• Evidence does not support a 'lower cholesterol is better' approach; optimal targets require further investigation.

Conclusions:

• Japanese studies confirm the association between lipid profiles and CHD risk.
• Lipid-lowering therapies are beneficial but require careful consideration of individual risk and treatment goals.
• Further research is needed to optimize hyperlipidemia treatment strategies for the Japanese population, considering unique epidemiological factors and drug response patterns.